Biotechnology - Vaccines

Filter

Current filters:

Vaccines

Popular Filters

1 to 25 of 70 results

Bavarian Nordic set to earn $975 million in Prostvac deal

Bavarian Nordic set to earn $975 million in Prostvac deal

04-03-2015

Danish biotech firm Bavarian Nordic has granted US pharma major Bristol-Myers Squibb an exclusive option…

Bavarian NordicBiotechnologyBristol-Myers SquibbLicensingOncologyProstvacVaccinesYervoy

NewLink earns $20 million Ebola vaccine milestone from Merck

19-02-2015

US biotech firm NewLink Genetics says it had received notification from pharma giant Merck & Co that…

BiotechnologyFinancialMerck & CoNewLink GeneticsResearchTropical diseasesVaccines

CSL delivers solid first-half financials, but guidance disappoints

11-02-2015

Australian plasma fractionation specialist CSL Limited has today announced a net profit after tax (NPAT)…

BiotechnologyCSL LimitedFinancialHematologyVaccines

Vaxxas secures equity funding of $20 million to further needle-free vaccine delivery system

Vaxxas secures equity funding of $20 million to further needle-free vaccine delivery system

10-02-2015

Biotech startup Vaxxas has secured equity funding of $20 million from new and existing investors to advance…

AustraliaBiotechnologyFinancialVaccinesVaxxas

Astellas Pharma in deal with Immunomic for JRC2-LAMP-vax, a vaccine for Japanese red cedar pollinosis

03-02-2015

US privately-held clinical-stage biotech firm Immunomic Therapeutics and the US subsidiary of Japanese…

Astellas PharmaBiotechnologyImmunomic TherapeuticsJapanJRC2-LAMP-vaxVaccines

Merck & Co inks discovery and development deal with Moderna

Merck & Co inks discovery and development deal with Moderna

13-01-2015

Privately-held Moderna Therapeutics has entered into a license and collaboration agreement with US pharma…

Anti-viralsBiotechnologyFinancialMerck & CoModerna TherapeuticsResearchUSAVaccines

Affinivax launches, aiming to develop novel conjugate vaccine

30-10-2014

Affinivax, a US biotechnology company dedicated to developing novel vaccines, today announced its launch…

AffinivaxBiotechnologyFinancialResearchVaccines

Fujifilm to expand biopharma CMO business with acquisition of Kalon

29-10-2014

Fujifilm Diosynth Biotechnologies USA, a subsidiary of Japanese digital camera and medical equipment…

BiotechnologyFujifilmFujifilm Diosynth BiotechnologiesKalon BiotherapeuticsMergers & AcquisitionsVaccines

UK cancer charity partners with Asterias Biotherapies on lung cancer vaccine

UK cancer charity partners with Asterias Biotherapies on lung cancer vaccine

15-09-2014

The charity Cancer Research UK and its commercialization arm Cancer Research Technology (CRT), have reached…

Asterias BiotherapeuticsBiotechnologyBioTimeCancer Research TechnologyLicensingOncologyResearchUKVaccines

iBio collaborates with Kanematsu Chemicals to target Japanese market

iBio collaborates with Kanematsu Chemicals to target Japanese market

14-08-2014

USA-based iBio Inc and Japan’s Kanematsu Chemicals, part of Kanematsu Corp have entered into a collaboration…

BiotechnologyBusiness FinanceiBio IncJapanKanematsuLicensingPharmacologyVaccines

Hemispherx links with SA biotech Bioclones on cancer vaccine

Hemispherx links with SA biotech Bioclones on cancer vaccine

14-07-2014

USA-based Hemispherx Biopharma has entered a strategic alliance to develop multiple projects with Bioclones,…

AlferonAmpligenBioclonesBiotechnologyHemispherx BioPharmaOncologyResearchSouth AfricaVaccines

FDA approval for Protein Sciences’ 2014/15 formulation of Flublok

FDA approval for Protein Sciences’ 2014/15 formulation of Flublok

09-07-2014

The US Food and Drug Administration has approved privately-held US biotech firm Protein Sciences’ strain…

BiotechnologyFlublokInfluenzaProtein Sciences CorpRegulationUSAVaccines

Novartis files for US approval of meningitis B vaccine Bexsero

Novartis files for US approval of meningitis B vaccine Bexsero

17-06-2014

Swiss pharma major Novartis has submitted a Biologic License Application to the US Food and Drug Administration…

BexseroBiotechnologyNovartisRegulationUSAVaccines

Novartis Vaccines appoints new Medical Affairs Director for North Europe

Novartis Vaccines appoints new Medical Affairs Director for North Europe

25-04-2014

Novartis Vaccines, the vaccination branch of Swiss drug major Novartis (NOVN: VX), has announced the…

BiotechnologyBoardroomNovartisPharmaceuticalUKVaccines

Dutch biotech Mucosis partners with Chinese firm

Dutch biotech Mucosis partners with Chinese firm

15-04-2014

Dutch biotech company Mucosis has entered into a long-term collaboration and license agreement with China-based…

BiotechnologyChangchunChief executiveChinaDiseaseHuman respiratory syncytial virusLicensingMimopath technologyNetherlandsVaccines

Valneva deal with Emergent BioSolutions for development of vaccines in the EB66 cell line

11-03-2014

European biotechnology company Valneva has signed a new research license agreement and transferred an…

BiotechnologyEB66 cell lineEmergent BioSolutionsLicensingVaccinesValneva

“Overwhelming approval” in store for Heplisav if Dynavax delivers sufficient safety data, says analyst

“Overwhelming approval” in store for Heplisav if Dynavax delivers sufficient safety data, says analyst

27-02-2014

Despite citing the need for further safety studies, both US and EU regulators have lauded the immunogenicity…

Anti-viralsBiotechnologyDynavax TechnologiesHeplisavRegulationResearchVaccines

Valneva initiates fourth antibody discovery program for Sanofi Pasteur

25-02-2014

European biotechnology company Valneva has initiated a fourth monoclonal antibody discovery program for…

Antibiotics and Infectious diseasesBiotechnologyLicensingResearchSanofiSanofi PasteurVaccinesValneva

Dynavax withdraws European MAA for Heplisav

18-02-2014

US biotech firm Dynavax Technologies says it has withdrawn the European Marketing Authorization Application…

Anti-viralsBiotechnologyDynavax TechnologiesEuropeHeplisavRegulationVaccines

Creation of ABIVAX - a leader in therapeutic vaccines - in a Cuban collaboration

12-02-2014

French venture capital firm Truffle Capital has announced the creation of Paris-based ABIVAX in collaboration…

ABIVAXAnti-viralsBiotechnologyResearchVaccines

BNDES invests 804 million real in Novartis' new Brazil biotechnology unit

BNDES invests 804 million real in Novartis' new Brazil biotechnology unit

07-12-2013

The Brazilian Development Bank will finance 804 million real ($342 million) for the construction of a…

BexseroBiotechnologyBrazilFinancialNovartisProductionSouth AmericaVaccines

1 to 25 of 70 results

Back to top